Breast cancer with biomarker reversal during the course of treatment: a case report.
biomarker
breast cancer
metastasis
re-biopsy
recurrence
Journal
Journal of surgical case reports
ISSN: 2042-8812
Titre abrégé: J Surg Case Rep
Pays: England
ID NLM: 101560169
Informations de publication
Date de publication:
Jun 2024
Jun 2024
Historique:
received:
01
05
2024
accepted:
17
06
2024
medline:
1
7
2024
pubmed:
1
7
2024
entrez:
1
7
2024
Statut:
epublish
Résumé
During breast cancer recurrence, drug therapy is planned based on the biological characteristics of the primary tumor. However, the mechanisms underlying these changes have not yet been clarified. A 59-year-old woman underwent breast cancer surgery 23 years previously and received postoperative hormone therapy for 2 years. She had abdominal distention and ascites effusion and was diagnosed with carcinomatous peritonitis due to luminal-type breast cancer after ascites puncture. She received up to the fourth line of treatment. Subsequently, pleural effusion was observed and human epidermal growth factor receptor 2 type breast cancer was diagnosed because of pleurodesis. This case suggests that the cell block diagnostic method based on thoracic and ascites fluid cytology is useful not only for confirming the primary tumor but also for diagnosing the biological characteristics of breast cancer. In the treatment of breast cancer recurrence, it is important to plan the treatment, including aggressive re-biopsy of metastases.
Identifiants
pubmed: 38947869
doi: 10.1093/jscr/rjae432
pii: rjae432
pmc: PMC11212497
doi:
Types de publication
Case Reports
Journal Article
Langues
eng
Pagination
rjae432Informations de copyright
Published by Oxford University Press and JSCR Publishing Ltd. © The Author(s) 2024.
Déclaration de conflit d'intérêts
All authors have no competing interests, financial or non-financial.